PURIFICATION OF ANTI-RBD ANTIBODIES OBTAINED FROM LLAMA (Lama glama) FOR POTENTIAL COVID-19 THERAPY

SOLIZ SANTANDER, SE; STAGNETTO, A; PLOPER, D; TOMAS GRAU, RH; ÁVILA, C; CAZORLA, S; MALDONADO GALDEANO, CAROLINA; ARGAÑARAZ, M; APICHELA, S; PERDIGÓN, G; CHEHÍN, R; VERA PINGITORE, E

Jornada; XXXVIII Jornadas Científicas - 2021 de la Asociación de Biología de Tucumán; 2021

Despite worldwide efforts to develop different treatments for SARS-CoV-2 COVID-19, the situation remains critical, requiring rapid and effective strategies. In this regard, antibodies (Ab) have demonstrated clinical potential. Among them, camelid nanoAb (VHH) arise as a possible alternative, as they recognize epitopes which are inaccessible to conventional Ab. Further advantages of VHH are their small size, high solubility, high stability and resistance to low pH. The aim of this work is to describe a purification scheme of different isotypes of anti-SARS-CoV-2 immunoglobulin G (IgG) produced after immunizing two llamas (Lama glama). To achieve this, plasma was injected into an affinity chromatographic column (Protein G), and the resulting fractions were analyzed by SDS-PAGE under non-reducing conditions. The anti-RBD titers were determined by an "in house" ELISA, reaching titers of 52000 and 13000 for IgG1 and IgG3 fractions, respectively. Subsequently, an affinity column (HiTrap NHS-activated) was prepared to separate monospecific anti-RBD polyclonal Ab. RBD produced in our laboratory was covalently coupled to this column, achieving a coupling efficiency of 97%. Different isotypes of monospecific anti-RBD Ab (IgG1140kDa e IgG395kDa) were obtained. IgG3 represent the starting point for obtaining VHH and/or evaluating their potential use as a therapeutic or preventive alternative, which represents a notable regional contribution in the fight against COVID-19.